Ost-müük Citius Pharmaceuticals, Inc. - CTXR CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.0278 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Citius Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 1.1464 |
| Avatud* | 1.1464 |
| Aastane muutus* | 25.98% |
| Päeva ulatus* | 1.1464 - 1.286 |
| 52 nädala ulatus | 0.77-1.71 |
| Keskmine maht (10 päeva) | 1.57M |
| Keskmine maht (3 kuud) | 29.46M |
| Turukapitalisatsioon | 174.74M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 158.86M |
| Tulu | N/A |
| EPS | -0.21 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.38 |
| Järgmine tuluaruande kuupäev | Aug 9, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| May 31, 2023 | 1.1364 | 0.0399 | 3.64% | 1.0965 | 1.1464 | 1.0965 |
| May 30, 2023 | 1.0965 | -0.0100 | -0.90% | 1.1065 | 1.1364 | 1.0965 |
| May 26, 2023 | 1.1065 | 0.0299 | 2.78% | 1.0766 | 1.1165 | 1.0766 |
| May 25, 2023 | 1.0766 | -0.0498 | -4.42% | 1.1264 | 1.1264 | 1.0666 |
| May 24, 2023 | 1.1065 | 0.0200 | 1.84% | 1.0865 | 1.1364 | 1.0666 |
| May 23, 2023 | 1.0965 | -0.0299 | -2.65% | 1.1264 | 1.1464 | 1.0666 |
| May 22, 2023 | 1.1264 | -0.0399 | -3.42% | 1.1663 | 1.1763 | 1.1264 |
| May 19, 2023 | 1.1663 | 0.0199 | 1.74% | 1.1464 | 1.1763 | 1.1264 |
| May 18, 2023 | 1.1165 | 0.0100 | 0.90% | 1.1065 | 1.1564 | 1.0866 |
| May 17, 2023 | 1.0866 | -0.1694 | -13.49% | 1.2560 | 1.2561 | 1.0467 |
| May 16, 2023 | 1.2461 | 0.0000 | 0.00% | 1.2461 | 1.2660 | 1.2261 |
| May 15, 2023 | 1.2660 | -0.1296 | -9.29% | 1.3956 | 1.4056 | 1.2261 |
| May 12, 2023 | 1.3956 | 0.0498 | 3.70% | 1.3458 | 1.4355 | 1.2860 |
| May 11, 2023 | 1.2959 | 0.0199 | 1.56% | 1.2760 | 1.4355 | 1.2760 |
| May 10, 2023 | 1.2461 | 0.0100 | 0.81% | 1.2361 | 1.2860 | 1.1962 |
| May 9, 2023 | 1.2261 | -0.0399 | -3.15% | 1.2660 | 1.2760 | 1.2261 |
| May 8, 2023 | 1.2660 | -0.0100 | -0.78% | 1.2760 | 1.2959 | 1.2461 |
| May 5, 2023 | 1.2660 | 0.0000 | 0.00% | 1.2660 | 1.2959 | 1.2361 |
| May 4, 2023 | 1.2461 | -0.0997 | -7.41% | 1.3458 | 1.3857 | 1.1962 |
| May 3, 2023 | 1.4854 | -0.0099 | -0.66% | 1.4953 | 1.5053 | 1.4654 |
Citius Pharmaceuticals, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Wednesday, August 9, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Citius Pharmaceuticals Inc Earnings Release Q3 2023 Citius Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Tulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 33.3161 | 23.3653 | 17.7107 | 15.5984 | 13.3391 |
| Müük/Üldine/admin kulud, kokku | 15.6606 | 11.2914 | 8.89788 | 7.00146 | 7.22622 |
| Uuringud ja arendus | 17.6555 | 12.2405 | 8.81281 | 8.5969 | 6.56293 |
| Tulud majandustegevusest | -33.3161 | -23.3653 | -17.7107 | -15.5984 | -13.3391 |
| Intressitulud (kulu), muud tulud, neto | 0.2514 | 0.25099 | 0.0524 | 0.03622 | -0.01584 |
| Netotulu enne makse | -33.0647 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Netotulu pärast makse | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Netotulu enne erikulusid | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Netotulu | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Arvestatav tulu, v a erikulud | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Arvestatav tulu, koos erikuludega | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Jaotamisele kuuluv netotulu | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Keskmine jaotamisele kuuluv aktsia kohta | 146.082 | 108.599 | 39.1652 | 20.1618 | 10.7319 |
| Jaotatav EPS, v a erakorralised kulud | -0.23029 | -0.22565 | -0.44805 | -0.77186 | -1.16817 |
| Jaotamisele kuuluv normaal-EPS | -0.23029 | -0.22718 | -0.44805 | -0.77186 | -1.2101 |
| Ootamatud kulutused (tulu) | 0 | -0.16656 | 0 | -0.45 | |
| Muud, neto | 0 | 0.05992 | 0.11021 | 0 | 0.81834 |
| Total Adjustments to Net Income | 0 | -1.45088 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Tulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 10.6853 | 3.66419 | 7.54957 | 8.91665 | 7.59063 |
| Müük/Üldine/admin kulud, kokku | 5.95845 | 3.80437 | 3.69234 | 4.02846 | 4.13842 |
| Uuringud ja arendus | 4.72686 | 3.44552 | 3.85723 | 4.88819 | 3.45221 |
| Tulud majandustegevusest | -10.6853 | -3.66419 | -7.54957 | -8.91665 | -7.59063 |
| Intressitulud (kulu), muud tulud, neto | 0.30328 | 0.21455 | 0.13483 | 0.05302 | 0.02957 |
| Muud, neto | 0 | 0 | |||
| Netotulu enne makse | -10.382 | -3.44965 | -7.41474 | -8.86363 | -7.56105 |
| Netotulu pärast makse | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Netotulu enne erikulusid | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Netotulu | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Arvestatav tulu, v a erikulud | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Arvestatav tulu, koos erikuludega | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Jaotamisele kuuluv netotulu | -10.526 | -3.59365 | -7.99074 | -8.86363 | -7.56105 |
| Keskmine jaotamisele kuuluv aktsia kohta | 146.252 | 146.211 | 146.146 | 146.13 | 146.042 |
| Jaotatav EPS, v a erakorralised kulud | -0.07197 | -0.02458 | -0.05468 | -0.06066 | -0.05177 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.07197 | -0.04052 | -0.05468 | -0.06066 | -0.05177 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Ootamatud kulutused (tulu) | 0 | -3.58569 | 0 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 44.5643 | 72.8143 | 13.982 | 7.94192 | 10.0601 |
| Raha ja lühiajalised investeeringud | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Raha ja ekvivalendid | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Prepaid Expenses | 2.85258 | 2.7414 | 0.12224 | 0.04811 | 0.05773 |
| Total Assets | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Property/Plant/Equipment, Total - Net | 0.65017 | 0.82985 | 0.98778 | 0.00059 | 0.00148 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 1.5868 |
| Intangibles, Net | 59.4 | 59.4 | 19.4 | 19.4 | 19.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.05709 | 0.05709 | 0.00217 |
| Total Current Liabilities | 4.53001 | 3.98229 | 4.09713 | 4.60772 | 3.18484 |
| Accounts Payable | 1.16538 | 1.2771 | 1.85624 | 2.71354 | 1.57344 |
| Accrued Expenses | 3.36463 | 2.7052 | 2.06793 | 1.72121 | 1.43843 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.17297 | 0.17297 | 0.17297 |
| Other Current Liabilities, Total | 0 | ||||
| Total Liabilities | 11.1734 | 10.2467 | 10.103 | 9.59352 | 3.18484 |
| Total Long Term Debt | 0 | 0 | 0.16458 | 0 | 0 |
| Total Equity | 102.826 | 132.182 | 33.6707 | 27.1529 | 27.8657 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.14621 | 0.14598 | 0.05558 | 0.02893 | 0.0162 |
| Additional Paid-In Capital | 232.368 | 228.084 | 104.209 | 80.1697 | 68.1073 |
| Retained Earnings (Accumulated Deficit) | -129.688 | -96.0478 | -70.5939 | -53.0458 | -40.2578 |
| Total Liabilities & Shareholders’ Equity | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Total Common Shares Outstanding | 146.211 | 145.979 | 55.577 | 28.9305 | 16.1988 |
| Laekumata arved, neto | 0.81834 | ||||
| Long Term Debt | 0 | 0.16458 | 0 | ||
| Deferred Income Tax | 5.5618 | 4.9858 | 4.9858 | 4.9858 | |
| Other Liabilities, Total | 0.48125 | 0.67823 | 0.85547 | ||
| Minority Interest | 0.60038 | 0.60038 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 34.9011 | 42.3174 | 44.5643 | 50.8345 | 58.2593 |
| Raha ja lühiajalised investeeringud | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Raha ja ekvivalendid | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Prepaid Expenses | 5.8356 | 5.43013 | 2.85258 | 2.79032 | 2.50311 |
| Total Assets | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Property/Plant/Equipment, Total - Net | 0.55484 | 0.60299 | 0.65017 | 0.69642 | 0.74177 |
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 9.3468 |
| Intangibles, Net | 59.4 | 59.4 | 59.4 | 59.4 | 59.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.03806 | 0.03806 | 0.03806 |
| Total Current Liabilities | 6.20968 | 4.53717 | 4.53001 | 4.46112 | 4.02192 |
| Accounts Payable | 2.72559 | 1.53758 | 1.16538 | 1.69052 | 1.70513 |
| Accrued Expenses | 3.48408 | 2.99959 | 3.36463 | 2.7706 | 2.3168 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.0347 | 11.2719 | 11.1734 | 10.5802 | 10.1904 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Deferred Income Tax | 5.8498 | 5.7058 | 5.5618 | 4.9858 | 4.9858 |
| Minority Interest | 0.60038 | 0.60038 | 0.60038 | 0.60038 | 0.60038 |
| Other Liabilities, Total | 0.37483 | 0.42857 | 0.48125 | 0.53288 | 0.5823 |
| Total Equity | 91.2061 | 100.433 | 102.826 | 109.736 | 117.596 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.14636 | 0.14621 | 0.14621 | 0.14613 | 0.14613 |
| Additional Paid-In Capital | 234.868 | 233.569 | 232.368 | 231.287 | 230.284 |
| Retained Earnings (Accumulated Deficit) | -143.808 | -133.282 | -129.688 | -121.698 | -112.834 |
| Total Liabilities & Shareholders’ Equity | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Total Common Shares Outstanding | 146.358 | 146.211 | 146.211 | 146.13 | 146.13 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Raha majandustegevusest | -28.3613 | -24.2504 | -16.9307 | -12.4377 | -11.3181 |
| Raha majandustegevusest | 0.00292 | 0.00149 | 0.00084 | 0.00089 | 0.00175 |
| Mittelikviidsed varad | 4.46091 | 1.5198 | 1.48355 | 0.92758 | 0.7069 |
| Cash Taxes Paid | |||||
| Makstud intressid | 0 | 0.00019 | |||
| Muutused tööjõus | 0.23956 | -2.71727 | -0.86697 | 2.19592 | 0.50985 |
| Tulu investeeringutelt | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Muud rahavood investeeringutelt, kokku | 0 | ||||
| Rahavood investeeringutelt | 0 | 120.471 | 22.8984 | 11.1475 | 17.298 |
| Rahavoogudesse investeerimine | 0 | 18.4504 | 0 | 0 | |
| Laenu väljastamine (kustutamine), neto | 0 | -0.17297 | 0.16458 | 0 | 0 |
| Rahaline kogumuutus | -28.3613 | 56.2132 | 5.96594 | -1.2902 | 5.9799 |
| Kapitalikulutused | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Aktsiate emiteerimine (tagasiost), neto | 0 | 102.193 | 22.7339 | 11.1475 | 17.298 |
| Deferred Taxes | 0.576 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.1197 | -3.59365 | -33.6407 | -25.6499 | -16.7863 |
| Cash From Operating Activities | -12.6774 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Operating Activities | 0.00146 | 0.00073 | 0.00292 | 0.00219 | 0.00146 |
| Non-Cash Items | 2.56255 | 1.24754 | 4.46091 | 3.3344 | 2.28611 |
| Changes in Working Capital | -1.40977 | -2.62306 | 0.23956 | 0.28456 | 0.18199 |
| Cash From Financing Activities | 0.03127 | 0 | 0 | 0 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.03127 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
| Net Change in Cash | -12.6462 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Investing Activities | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | |||
| Deferred Taxes | 0.288 | 0.144 | 0.576 | ||
| Other Investing Cash Flow Items, Total | 0 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Mazur (Leonard L) | Individual Investor | 6.4557 | 10255342 | -1 | 2022-11-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8112 | 6054328 | 40301 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 1.5265 | 2425000 | -3743361 | 2021-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4586 | 2317168 | 4868 | 2023-03-31 | LOW |
| Holubiak (Myron Z) | Individual Investor | 1.2541 | 1992243 | 0 | 2022-11-30 | |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8428 | 1338777 | 6154 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3 | 476597 | 34000 | 2023-03-31 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2893 | 459511 | 130223 | 2023-03-31 | MED |
| GSA Capital Partners LLP | Hedge Fund | 0.2849 | 452561 | -46222 | 2023-03-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.2513 | 399270 | -9900 | 2023-03-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.1917 | 304482 | -246644 | 2023-03-31 | HIGH |
| Jane Street Capital, L.L.C. | Research Firm | 0.1549 | 246023 | 224990 | 2023-03-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1541 | 244755 | 7008 | 2023-03-31 | LOW |
| Hightower Advisors, LLC | Investment Advisor | 0.1317 | 209198 | 14713 | 2023-03-31 | LOW |
| Inspire Advisors, LLC | Investment Advisor | 0.125 | 198632 | 2686 | 2023-03-31 | LOW |
| Wealth Advisory Solutions, L.L.C. | Investment Advisor | 0.0981 | 155850 | 0 | 2023-03-31 | |
| AHL Partners LLP | Investment Advisor | 0.0836 | 132826 | 86615 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0759 | 120521 | 31943 | 2023-03-31 | MED |
| Qube Research & Technologies Ltd | Hedge Fund | 0.063 | 100106 | -20474 | 2023-03-31 | HIGH |
| Kestra Advisory Services, LLC | Investment Advisor | 0.0579 | 91917 | -1800 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Citius Pharmaceuticals, Inc. Company profile
Ettevõttest Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc. spetsialiseeritud farmaatsiaettevõte. Ettevõte arendab ja turustab intensiivravi tooteid, keskendudes infektsioonivastastele toodetele vähiravis, retseptiravimitele ja mesenhümaatilisele tüvirakuteraapiale. Tal on viis toodet: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite ja I/ONTAK. Mino-Lok on antibiootikumide lukustuslahus, mida kasutatakse kateetriga seotud vereringeinfektsioonidega patsientide raviks, päästes nakatunud kateetri. Mino-Wrap on vedeldav geelipõhine mähis, mis vähendab koeekspandri infektsioone pärast rinna rekonstruktiivseid operatsioone. Halo-Lido on kortikosteroid-lidokaiini paikselt manustatav preparaat, mis on mõeldud põletikuvastaseks ja anesteetiliseks leevenduseks hemorroidide all kannatavatele inimestele. NoveCite on mesenhümaatiliste tüvirakkude ravi ARDSi raviks. I/ONTAK on muundatud IL-2 difteeria toksiini fusioonvalk, mis on mõeldud püsiva või korduva T-rakkude lümfoomiga patsientide raviks.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Commerce Dr Fl 1
CRANFORD
NEW JERSEY 07016-3501
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com